SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jun 1, 2026

QTTB

Q32 Bio Inc.
BULLISH
Impact 8/10
Horizonweeks Processed5mo ago
Insider cluster: 2 insiders, $20.0M total
Actionable Insight ▲ Bullish

Insider buying at the PIPE price suggests management views the stock as undervalued. The PIPE provides balance sheet support, reducing near-term financing risk. Monitor for pipeline catalysts (phase updates) that could drive re-rating.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$12.64
T+0 close · Jun 1, 2026 · via day close
Latest settled
+28.01%
T+60 · $16.18
Vs SPY
+26.89%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $12.64entry
  2. T+1 · 6mo ago −3.56%α −2.84% · $12.19
  3. T+5 · 5mo ago −5.93%α −2.97% · $11.89
  4. T+20 · 5mo ago −0.32%α +1.25% · $12.60
  5. T+60 · 3mo ago +28.01%α +26.89% · $16.18

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Directors OrbiMed Advisors and Xu Diyong each purchased $10M of QTTB common stock at $8/share on May 28, 2026, for a total of $20M (10.1% of market cap). These open-market purchases coincide with a PIPE offering disclosed in the May 27 8-K, indicating insider participation and strong confidence at the offering price.

Key Financial Metrics

Direction
buying
Total Value
$20.0M
Insiders
2

Key Facts

  • OrbiMed Advisors LLC and Xu Diyong each bought 1,250,000 shares at $8.00 on 2026-05-28, total $20M.
  • Total insider purchase equals ~10.1% of QTTB's $198M market cap.
  • Purchases follow a Securities Purchase Agreement (8-K filed 2026-05-27) for a PIPE offering at the same $8 price.
  • Both buyers are directors and 10% owners, amplifying the signal.

Financial Impact

Insiders invested $20M at $8/share, representing 10.1% of market cap; PIPE likely raises additional capital from other investors.

dilutioncashinsider ownership

Risk Factors

  • PIPE dilutes existing shareholders; new shares represent a significant overhang.
  • Clinical-stage biotech risk; pipeline failure could impair recovery.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-QTTB-1780362955879

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026